These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8291508)

  • 21. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical role of d-sotalol and d,l-sotalol in supraventricular arrhythmias, including pre-excitation.
    Daubert C; Mabo P; Gras D; Leclercq C
    Eur Heart J; 1993 Nov; 14 Suppl H():67-73. PubMed ID: 7904939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sotalol hydrochloride (Betapace): a new antiarrhythmic drug.
    Dunnington CS
    Am J Crit Care; 1993 Sep; 2(5):397-406. PubMed ID: 8220672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Action of sotalol on potential reentrant pathways and ventricular tachyarrhythmias in conscious dogs in the late postmyocardial infarction phase.
    Cobbe SM; Hoffman E; Ritzenhoff A; Brachmann J; Kübler W; Senges J
    Circulation; 1983 Oct; 68(4):865-71. PubMed ID: 6616781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is class III antiarrhythmic activity important?
    Singh BN
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():597-602. PubMed ID: 2275889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sotalol: Current Status and Expanding Indications.
    Singh BN
    J Cardiovasc Pharmacol Ther; 1999 Jan; 4(1):49-65. PubMed ID: 10684524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia.
    Saul JP; Ross B; Schaffer MS; Beerman L; Melikian AP; Shi J; Williams J; Barbey JT; Jin J; Hinderling PH;
    Clin Pharmacol Ther; 2001 Mar; 69(3):145-57. PubMed ID: 11240979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Electrophysiologic properties of sotalol and d-sotalol. A current view.
    Touboul P
    Eur Heart J; 1993 Nov; 14 Suppl H():24-9. PubMed ID: 7904935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of sotalol for therapy of complex ventricular arrhythmias and comparisons with placebo and class I antiarrhythmic drugs.
    Anderson JL
    Am J Cardiol; 1990 Jan; 65(2):37A-42A; discussion 51A-52A. PubMed ID: 2403734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppressant effects of conventional beta blockers and sotalol on complex and repetitive ventricular premature complexes.
    Deedwania PC
    Am J Cardiol; 1990 Jan; 65(2):43A-50A; discussion 51A-52A. PubMed ID: 1688482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.
    Singh BN; Deedwania P; Nademanee K; Ward A; Sorkin EM
    Drugs; 1987 Sep; 34(3):311-49. PubMed ID: 3315621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
    Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML
    Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death.
    Lynch JJ; Coskey LA; Montgomery DG; Lucchesi BR
    Am Heart J; 1985 May; 109(5 Pt 1):949-58. PubMed ID: 3993529
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiarrhythmic and antifibrillatory actions of the beta adrenergic receptor antagonist, dl-sotalol.
    Patterson E; Lynch JJ; Lucchesi BR
    J Pharmacol Exp Ther; 1984 Aug; 230(2):519-26. PubMed ID: 6086892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Symposium on the management of ventricular dysrhythmias. Antifibrillatory versus antiectopic therapy.
    Anderson JL
    Am J Cardiol; 1984 Jul; 54(2):7A-13A. PubMed ID: 6147079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short- and long-term antiarrhythmic and hemodynamic effects of d,l-sotalol in patients with symptomatic ventricular arrhythmias.
    Hohnloser SH; Zabel M; Krause T; Just H
    Am Heart J; 1992 May; 123(5):1220-4. PubMed ID: 1575137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term sotalol therapy in patients with ventricular arrhythmias.
    Mary-Rabine L; Soumagne D; Stiels B
    Acta Cardiol; 1986; 41(2):89-97. PubMed ID: 2424202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term results of electrophysiologically guided sotalol therapy for life-threatening ventricular arrhythmias.
    Lee RJ; Wong M; Siu A; Namekawa-Wong M; Epstein LM; Fitzpatrick AP; Grogin HR; Scheinman MM; Lesh MD
    Am Heart J; 1996 Nov; 132(5):973-8. PubMed ID: 8892770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, safety, and tolerance of d-sotalol in patients with refractory supraventricular tachyarrhythmias.
    Sahar DI; Reiffel JA; Bigger JT; Squatrito A; Kidwell GA
    Am Heart J; 1989 Mar; 117(3):562-8. PubMed ID: 2919535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.